These results suggest that CGRP receptors, Panx-1 channels and connexin hemichannels are potential targets for the design of novel pharmacological strategies for the treatment of the complications related to the NO deficiency and endothelial dysfunction associated to inflammation. Here, PANX1 is linked to endothelial dysfunction.